作者: Camille Beauduy , Conan MacDougall
DOI: 10.1310/HPJ4802-S7
关键词:
摘要: Clostridium difficile infection (CDI) is a major cause of morbidity and mortality, both in hospitalized patients the community. Despite importance CDI, therapeutic options remain limited. The Society for Hospital Epidemiology America Infectious Diseases published guidelines CDI management 2010. Recommendations based on randomized controlled trial data include metronidazole or oral vancomycin mild to moderate disease severe disease. Since publication these guidelines, fidaxomicin has been approved trials showing similar clinical cure rates lower recurrence rate compared vancomycin. Patients with fulminant, complicated, multiply recurrent have not included trials, so decisions are supported by observational anecdotal studies. Epidemiologic studies consistently identify systemic antibiotic use as risk factor development CDI. This tends in...